Home LiteratureArticle Details
PMID: 9343206 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Analysis of the murine leukemia virus R peptide: delineation of the molecular determinants which are important for its fusion inhibition activity.

Journal of virology ·Vol. 71 ·No. 11 ·1997-11-00 ·Pages 8490-6

Yang C, Compans RW

Abstract

In previous studies, the C-terminal R peptide of the murine leukemia virus (MuLV) Env protein was shown to be a potent inhibitor of viral fusion activity. In the present study, we investigated the molecular determinants in the MuLV Env protein cytoplasmic tail which are important for the fusion inhibition activity of the R peptide. We constructed a series of mutant MuLV env genes which express Env proteins with serial truncations, internal deletions, or amino acid substitutions in the cytoplasmic tail. To analyze their cell fusion activity, we employed a quantitative fusion assay. We found that truncations of up to 7 amino acids from the C terminus of the cytoplasmic tail had no detectable effect on the lack of fusion activity of the full-length Env protein; however, further truncations resulted in a progressive increase in cell fusion activity. Studies of mutant proteins with amino acid substitutions in the cytoplasmic tail showed that Leu-627 plays an important role in fusion inhibition by the R peptide, while most of the other amino acids in the R peptide were not essential for fusion inhibition. Studies of mutant proteins with internal deletions upstream of the cleavage site in the cytoplasmic tail showed that this region is also involved in fusion inhibition by the R peptide, although only to a limited extent. The results are consistent with a model in which the MuLV R peptide exhibits its fusion inhibition activity through interaction with a cellular factor(s).

MeSH Terms
Amino Acid Sequence Cytoplasm/chemistry Gene Products, env/chemistry HeLa Cells Humans Leukemia Virus, Murine/chemistry Membrane Fusion Molecular Sequence Data Peptide Fragments Sequence Alignment Sequence Deletion Structure-Activity Relationship
Chemicals
Gene Products, env Peptide Fragments
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Yang C
Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
Compans R W
References (43)
43 references, click to expand
  1. The cytoplasmic domain of simian immunodeficiency virus transmembrane protein modulates infectivity.
    J Virol. 1989 Oct;63(10):4395-403 PMID: 2778881
  2. DNA sequencing with chain-terminating inhibitors.
    Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463-7 PMID: 271968
  3. The pH independence of mammalian retrovirus infection.
    J Gen Virol. 1990 Apr;71 ( Pt 4):767-73 PMID: 2157795
  4. Viral and cellular membrane fusion proteins.
    Annu Rev Physiol. 1990;52:675-97 PMID: 2184772
  5. Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses.
    J Virol. 1991 Jan;65(1):31-41 PMID: 1985202
  6. Re-evaluation of the involvement of the adhesion molecules ICAM-1/LFA-1 in syncytia formation of HIV-1-infected subclones of a CEM T-cell leukemic line.
    AIDS Res Hum Retroviruses. 1991 Jan;7(1):45-53 PMID: 1707641
  7. Receptor choice determinants in the envelope glycoproteins of amphotropic, xenotropic, and polytropic murine leukemia viruses.
    J Virol. 1992 Mar;66(3):1468-75 PMID: 1310758
  8. Cytoplasmic domain truncation enhances fusion activity by the exterior glycoprotein complex of human immunodeficiency virus type 2 in selected cell types.
    J Virol. 1992 Jun;66(6):3971-5 PMID: 1583738
  9. HIV-induced syncytium formation requires the formation of conjugates between virus-infected and uninfected T-cells in vitro.
    AIDS. 1991 Dec;5(12):1425-32 PMID: 1687645
  10. Effect of retroviral proteinase inhibitors on Mason-Pfizer monkey virus maturation and transmembrane glycoprotein cleavage.
    J Virol. 1992 Jul;66(7):4220-7 PMID: 1602542
  11. Retained in vitro infectivity and cytopathogenicity of HIV-1 despite truncation of the C-terminal tail of the env gene product.
    Virology. 1992 Jul;189(1):167-77 PMID: 1604808
  12. Basis for receptor specificity of nonecotropic murine leukemia virus surface glycoprotein gp70SU.
    J Virol. 1992 Aug;66(8):4632-8 PMID: 1321266
  13. Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity.
    J Virol. 1992 Nov;66(11):6616-25 PMID: 1357190
  14. Membrane fusion.
    Science. 1992 Nov 6;258(5084):917-24 PMID: 1439803
  15. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160.
    Nature. 1992 Nov 26;360(6402):358-61 PMID: 1360148
  16. Cell fusion induced by the murine leukemia virus envelope glycoprotein.
    J Virol. 1993 Jan;67(1):67-74 PMID: 8416389
  17. Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein increases env incorporation into particles and fusogenicity and infectivity.
    J Virol. 1993 May;67(5):2824-31 PMID: 8474176
  18. A spring-loaded mechanism for the conformational change of influenza hemagglutinin.
    Cell. 1993 May 21;73(4):823-32 PMID: 8500173
  19. Paramyxovirus fusion: a hypothesis for changes.
    Virology. 1993 Nov;197(1):1-11 PMID: 8212546
  20. Cell fusion activity of the simian immunodeficiency virus envelope protein is modulated by the intracytoplasmic domain.
    Virology. 1993 Nov;197(1):255-64 PMID: 8212561
  21. Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein alters the conformation of the external domain.
    J Virol. 1994 Feb;68(2):585-91 PMID: 8289362
  22. Function of the cytoplasmic domain of a retroviral transmembrane protein: p15E-p2E cleavage activates the membrane fusion capability of the murine leukemia virus Env protein.
    J Virol. 1994 Mar;68(3):1773-81 PMID: 8107239
  23. Uncoupled expression of Moloney murine leukemia virus envelope polypeptides SU and TM: a functional analysis of the role of TM domains in viral entry.
    J Virol. 1994 May;68(5):3207-19 PMID: 7512161
  24. pH-independent murine leukemia virus ecotropic envelope-mediated cell fusion: implications for the role of the R peptide and p12E TM in viral entry.
    J Virol. 1994 May;68(5):3220-31 PMID: 8151784
  25. Postassembly cleavage of a retroviral glycoprotein cytoplasmic domain removes a necessary incorporation signal and activates fusion activity.
    J Virol. 1994 Jul;68(7):4620-7 PMID: 8207836
  26. Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation.
    J Virol. 1994 Sep;68(9):5411-22 PMID: 8057423
  27. A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cells.
    J Virol. 1995 Sep;69(9):5217-27 PMID: 7636963
  28. Differences in the role of the cytoplasmic domain of human parainfluenza virus fusion proteins.
    J Virol. 1995 Nov;69(11):7045-53 PMID: 7474124
  29. Analysis of the cell fusion activities of chimeric simian immunodeficiency virus-murine leukemia virus envelope proteins: inhibitory effects of the R peptide.
    J Virol. 1996 Jan;70(1):248-54 PMID: 8523533
  30. Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
    Nature. 1970 Aug 15;227(5259):680-5 PMID: 5432063
  31. Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes.
    Mol Cell Biol. 1987 Jul;7(7):2538-44 PMID: 3112559
  32. Sequence-specific antibodies show that maturation of Moloney leukemia virus envelope polyprotein involves removal of a COOH-terminal peptide.
    Proc Natl Acad Sci U S A. 1981 Oct;78(10):6023-7 PMID: 6947213
  33. Quantitative separation of murine leukemia virus proteins by reversed-phase high-pressure liquid chromatography reveals newly described gag and env cleavage products.
    J Virol. 1984 Nov;52(2):492-500 PMID: 6333515
  34. Maturation of murine leukemia virus env proteins in the absence of other viral proteins.
    Virology. 1985 Sep;145(2):335-9 PMID: 2992156
  35. Binding of the human retrovirus HTLV-III/LAV/ARV/HIV to the CD4 (T4) molecule: conformation dependence, epitope mapping, antibody inhibition, and potential for idiotypic mimicry.
    J Immunol. 1986 Nov 1;137(9):2937-44 PMID: 2428879
  36. Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus.
    Cell. 1987 Jul 31;50(3):327-8 PMID: 3496970
  37. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity.
    J Virol. 1988 Jan;62(1):139-47 PMID: 3257102
  38. Glycosylation and processing of the human immunodeficiency virus type 1 envelope protein.
    J Acquir Immune Defic Syndr. 1989;2(2):163-9 PMID: 2649653
  39. Involvement of a leukocyte adhesion receptor (LFA-1) in HIV-induced syncytium formation.
    Science. 1989 Jun 2;244(4908):1075-8 PMID: 2543075
  40. Virus entry into animal cells.
    Adv Virus Res. 1989;36:107-51 PMID: 2500008
  41. Protein-mediated membrane fusion.
    Annu Rev Biophys Biophys Chem. 1989;18:187-211 PMID: 2660823
  42. Characterization of retrovirus-induced SC-1 cell fusion.
    Virus Res. 1995 Aug;37(3):177-98 PMID: 8533456
  43. SIV adaptation to human cells.
    Nature. 1989 Oct 19;341(6243):573-4 PMID: 2677749
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
1997-11-00
Pages
8490-6
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC192312
Subset
IM
Grants
NIAID NIH HHS · AI 34242 · United States
NCI NIH HHS · CA 18611 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com